The $54 billion acquisition by US pharmaceuticals company AbbVie of UK-listed rival Shire announced in July summed up many of the key trends in mergers and acquisitions this year.

It was a multibillion-dollar deal. It was cross-border. And it involved a US company doing a deal, at least in part, to minimise its tax bill.